Maravai LifeSciences Reports Q3 2026 Financial Results
Maravai LifeSciences Holdings, Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for both revenue and earnings per share.
Stocks · News reference
KeyBanc Capital Markets has upgraded Maravai LifeSciences Holdings, Inc. from Sector Weight to Overweight, setting a price target of $11.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Maravai LifeSciences Holdings, Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for both revenue and earnings per share.
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
Maravai LifeSciences has scheduled an investor conference appearance for November 2026, featuring a fireside chat with its Chief Financial Officer.
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by